Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin
Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (aminosidine) and gentamicin
复制标题
DOI：
10.2307/3285646
复制
发表时间：
1999-04-01
影响因子：
1.3
通讯作者：
Berman, JD
中科院分区：
文献类型：
--
作者：
Grogl, M;Schuster, BG;Berman, JD
皮肤利什曼病目前用一种经常有毒的药物(锑)进行为期20天的非肠道治疗。在软白色石蜡中外用的帕罗霉素(15%)加甲基苯乙氯铵(MBCL，12%)或尿素(10%)的局部配方已被测试用于治疗人类的新旧世界疾病。我们比较了一种新的外用制剂WR 279,396(帕罗霉素[15%]+庆大霉素[0.5%])与临床制剂治疗BALB/c小鼠皮肤病的疗效。60天前的皮损每天治疗两次，连续10天，并在接下来的70天内确定对治疗的反应。对于由大利什曼原虫或墨西哥利什曼原虫引起的溃疡，WR 279,396组在治疗后第20天100%的病变愈合，到第70天没有复发；在帕罗霉素-MBCL组有83%的病变愈合而没有复发。帕罗米星-尿素组在30d时大面积皮损100%愈合，30%复发。对于由泛美利什曼原虫或亚马逊利什曼原虫引起的溃疡，用WR 179,396治疗的所有皮损都愈合了，并且没有复发：
Cutaneous leishmaniasis is presently treated with 20 days of parenteral therapy with a frequently toxic drug (antimony). Topical formulations of paromomycin (15%) plus methylbenzethonium chloride (MBCL, 12%) or plus urea (10%) in soft white paraffin have been tested for Old and New World disease in humans. We compared the efficacy of a new topical formulation, WR 279,396 (paromomycin [15%] plus gentamicin [0.5%]) to the clinical formulations in the treatment of cutaneous disease in BALB/c mice. Sixty-day-old lesions were treated twice a day for 10 days, and the response to therapy was determined over a further 70 days. For ulcers due to Leishmania major or to Leishmania mexicana, 100% of lesions in the WR 279,396 group healed by day 20 after therapy and did not relapse by day 70; 83% of lesions healed without relapse in the paromomycin-MBCL group. In the paromomycin-urea group, 100% of L. major lesions healed by day 30 but 30% relapsed. For ulcers due to Leishmania panamensis or Leishmania amazonensis, all lesions treated with WR 179,396 healed and did not relapse: